Contribution of NIH funding to new drug approvals 2010–2016

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 10, 2018, Pages 2329-2334

  Cleary, Ekaterina Galkina ^a   Beierlein, Jennifer M ^a   Khanuja, Navleen Surjit ^a   McNamee, Laura M ^a   Ledley, Fred D ^a  

^a BENTLEY UNIVERSITY   (United States)

Author keywords

Basic science; Drug development; NIH funding; Translational science

Indexed keywords

DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; FINANCIAL MANAGEMENT; HEALTH CARE COST; MEDICAL RESEARCH; MORBIDITY; NATIONAL HEALTH ORGANIZATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; DRUG DEVELOPMENT; ECONOMICS; HUMAN; STATISTICS AND NUMERICAL DATA; TRANSLATIONAL RESEARCH; UNITED STATES;

DRUG APPROVAL; DRUG DISCOVERY; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); TRANSLATIONAL MEDICAL RESEARCH; UNITED STATES;

EID: 85042918200     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1715368115     Document Type: Review

References (63)

1. Stokes DE (2011) Pasteur’s Quadrant: Basic Science and Technological Innovation (Brookings Institute, Washington, DC).
2. Collins FS (2011) Reengineering translational science: The time is right. Sci Transl Med 3:90cm17.
3. Moses H, 3rd, et al. (2015) The anatomy of medical research: US and international comparisons. JAMA 313:174–189.
4. Cockburn I, Henderson R (1996) Public-private interaction in pharmaceutical research. Proc Natl Acad Sci USA 93:12725–12730.
5. Zycher B, DiMasi JA, Milne C-P (2010) Private sector contributions to pharmaceutical science: Thirty-five summary case histories. Am J Ther 17:101–120.
6. Chakravarthy R, Cotter K, DiMasi J, Milne C-P, Wendel N (2016) Public-and private-sector contributions to the research and development of the most transformational drugs in the past 25 years: From theory to therapy. Ther Innov Regul Sci 50:759–768.
7. Reichert JM, Milne C-P (2002) Public and private sector contributions to the discovery and development of “impact” drugs. Am J Ther 9:543–555.
8. Varmus H (2006) The new era in cancer research. Science 312:1162–1165.
9. Woodcock J, Brumfield M, Gill D, Zerhouni E (2014) The driving role of consortia on the critical path to innovative therapies. Nat Rev Drug Discov 13:781–782.
10. DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ 47:20–33.
11. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: New estimates of drug development costs. J Health Econ 22:151–185.
12. Munos B (2009) Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8:959–968.
13. Scannell JW, Blanckley A, Boldon H, Warrington B (2012) Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov 11:191–200.
14. DiMasi JA, Grabowski HG (2007) The cost of biopharmaceutical R&D: Is biotech different? Manage Decis Econ 28:469–479.
15. DiMasi JA, Grabowski HG, Vernon J (2004) R&D costs and returns by therapeutic category. Drug Inf J 38:211–223.
16. Stevens AJ, et al. (2011) The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 364:535–541.
17. US Food & Drug Administration (2017) Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Available at https://www.accessdata.fda.gov/scripts/cder/ob/. Accessed April 12, 2017.
18. Kaitin KI, Bryant NR, Lasagna L (1993) The role of the research-based pharmaceutical industry in medical progress in the United States. J Clin Pharmacol 33:412–417.
19. Sampat BN (2009) Academic patents and access to medicines in developing countries. Am J Public Health 99:9–17.
20. Sampat BN, Lichtenberg FR (2011) What are the respective roles of the public and private sectors in pharmaceutical innovation? Health Aff (Millwood) 30:332–339.
21. Kneller R (2010) The importance of new companies for drug discovery: Origins of a decade of new drugs. Nat Rev Drug Discov 9:867–882.
22. Patridge EV, Gareiss PC, Kinch MS, Hoyer DW (2015) An analysis of original research contributions toward FDA-approved drugs. Drug Discov Today 20:1182–1187.
23. Cockburn IM, Henderson RM (2000) Publicly funded science and the productivity of the pharmaceutical industry. Innov Policy Econ 1:1–34.
24. McNamee LM, Walsh MJ, Ledley FD (2017) Timelines of translational science: From technology initiation to FDA approval. PLoS One 12:e0177371.
25. McNamee LM, Ledley FD (2012) Patterns of technological innovation in biotech. Nat Biotechnol 30:937–943.
26. Beierlein JM, et al. (2017) Landscape of innovation for cardiovascular pharmaceuticals: From basic science to new molecular entities. Clin Ther 39:1409–1425.e20.
27. Beierlein JM, McNamee LM, Walsh MJ, Ledley FD (2015) Patterns of innovation in Alzheimer’s disease drug development: A strategic assessment based on technological maturity. Clin Ther 37:1643–51.e3.
28. McNamee LM, Ledley FD (2017) Modeling timelines for translational science in cancer; the impact of technological maturation. PLoS One 12:e0174538.
29. Swinney DC (2013) Phenotypic vs. target-based drug discovery for first-in-class medicines. Clin Pharmacol Ther 93:299–301.
30. Swinney DC, Anthony J (2011) How were new medicines discovered? Nat Rev Drug Discov 10:507–519.
31. Drews J (2000) Drug discovery: A historical perspective. Science 287:1960–1964.
32. Gibbs JB (2000) Mechanism-based target identification and drug discovery in cancer research. Science 287:1969–1973.
33. Gabor Miklos GL (2005) The human cancer genome project–One more misstep in the war on cancer. Nat Biotechnol 23:535–537.
34. Kotz J (2012) Phenotypic screening, take two. Sci Bus Exch, 10.1038/scibx.2012.380.
35. US Food & Drug Administration (2017) New molecular entity (NME) drug and new biologic approvals. Available at https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/DrugandBiologicApprovalReports/NDAandBLAApprovalReports/ucm373420.htm. Accessed April 12, 2017.
36. US Food & Drug Administration (2017) New drugs at FDA: CDER’s new molecular entities and new therapeutic biological products. Available at https://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/default.htm. Accessed April 12, 2017.
37. US Food & Drug Administration (2017) FDA online label repository. Available at https://labels.fda.gov/. Accessed April 12, 2017.
38. EMBL-EBI (2017) ChEMBL. Available at https://www.ebi.ac.uk/chembl/. Accessed April 12, 2017.
39. National Institutes of Health (2017) Research portfolio online reporting tools (RePORTER), ExPORTER data catalog. Available at https://exporter.nih.gov/ExPORTER_Catalog.aspx. Accessed April 12, 2017.
40. United States Department of Labor (2017) Bureau of labor statistics: CPI-All urban consumers (current series). Available at: https://data.bls.gov/timeseries/CUUR0000SA0. Accessed April 12, 2017.
41. Xu Q, Boggio A, Ballabeni A (2014) Countries’ biomedical publications and attraction scores. A PubMed-based assessment. F1000 Res 3:292.
42. Boyack KW, Jordan P (2011) Metrics associated with NIH funding: A high-level view. J Am Med Inform Assoc 18:423–431.
43. National Institutes of Health (2009) NIH’s role in the American recovery and reinvestment Act (ARRA). Available at https://www.nih.gov/about-nih/who-we-are/nih-director/statements/nihs-role-american-recovery-reinvestment-act-arra. Accessed April 12, 2017.
44. Collins FS (2012) NIH basics. Science 337:503.
45. National Research Council (2005) Assessment of Department of Defense Basic Research (The National Academies, Washington, DC), p 70.
46. Legal Information Institute (1952) 35 US Code § 101– Inventions patentable. Code of Federal Regulations. Available at https://www.law.cornell.edu/uscode/text/35/101. Accessed April 12, 2017.
47. United States Patent and Trademark Office (2017) Guidelines for examination of applications for compliance with the utility requirement [R-11.2013]. Available at https://www.uspto.gov/web/offices/pac/mpep/s2107.html. Accessed April 12, 2017.
48. European Patent Office (2017) Convention on the grant of European patents, article 52 – Patentable inventions. Available at www.epo.org/law-practice/legal-texts/html/epc/2016/e/ar52.html. Accessed April 12, 2017.
49. Pavitt K (1998) Do patents reflect the useful research output of universities? Res Eval 7:105–111.
50. Roach M, Cohen WM (2013) Lens or prism? Patent citations as a measure of knowledge flows from public research. Manage Sci 59:504–525.
51. Bishop JM, Kirschner M, Varmus H (1993) Science and the new administration. Science 259:444–445.
52. Kornberg A (1997) The NIH did it! Science 278:1863.
53. Lauer M (2016) NIH’s commitment to basic science. Extramural Nexus. Available at https://nexus.od.nih.gov/all/2016/03/25/nihs-commitment-to-basic-science/. Accessed April 12, 2017.
54. Santos FM (2003) The coevolution of firms and their knowledge environment: Insights from the pharmaceutical industry. Technol Forecast Soc Change 70:687–715.
55. Enkel E, Gassmann O, Chesbrough H (2009) Open R&D and open innovation: Exploring the phenomenon. R & D Manag 39:311–316.
56. Sampat BN (2012) Mission-oriented biomedical research at the NIH. Res Policy 41: 1729–1741.
57. Research America (2016) US investments in medical and health research and development, 2013-2015. Available at https://www.researchamerica.org/sites/default/files/2016US_Invest_R%26D_report.pdf. Accessed April 12, 2017.
58. Reardon S, Tollefson J, Witze A, Ross E (2017) Trump budget would slash science programmes across government. Nature 546:19–20.
59. Matthews KR, Evans KM, Lane NF (2017) Science advice in the trump white house. Science 355:574–576.
60. Ioannidis JP, et al. (2014) Increasing value and reducing waste in research design, conduct, and analysis. Lancet 383:166–175.
61. Chalmers I, et al. (2014) How to increase value and reduce waste when research priorities are set. Lancet 383:156–165.
62. Ioannidis JP (2014) How to make more published research true. PLoS Med 11: e1001747.
63. Arora A, Belenzon S, Patacconi A (2015) Killing the golden goose? The decline of science in corporate R&D (National Bureau of Economic Research). Available at www.nber.org/papers/w20902. Accessed April 12, 2017.